LapCorp stops selling the controversial ovarian cancer screening test, after being warned by the FDA:

The case has raised questions about the degree to which the F.D.A. can or should regulate diagnostic tests.

Doctors have long sought a test that could detect ovarian cancer early, when the condition would be more treatable. But some experts had said that LabCorp’s test, called OvaSure, had not been proved to work.

Screening for ovarian cancer has not been shown to save lives, and results in unnecessary procedures from false positives.

Having the FDA regulate diagnostic tests isn’t a bad idea. Many companies unscrupulously profit from the public’s “more screening is better medicine” mentality, especially with the advent of genetic screening tests.

Regulating tests can reduce unproven screening, which will cut down on the number of false positives leading to unnecessary procedures.